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SUPPLEMENTARY NOTES
ABSTRACT
The objective of this research is to further our understanding of the molecular mechanisms underlying the aggressive growth of estrogen receptor (ER)-negative, basal-like breast tumors. My goal is to determine if SKP2 is a viable new therapeutic target to specifically treat patients who have tumors that are independent of ER signaling. The most significant result was the establishment of a TMX2-28 cell line that has been stably transfected with a SKP2-shRNA construct. This cell line will be instrumental in elucidating the role that SKP2 plays in breast cancer progression.
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The objective of this research is to further our understanding of the cellular and molecular mechanisms underlying the aggressive growth of ER-negative, basal-like tumors. The goal is to identify new therapeutic targets to specifically treat patients that have tumors that are independent of ER signaling as these tumors are more often ER-negative. Past work from our lab and others has suggested that S-phase kinase-associated protein 2 (SKP2) plays an important role in breast tumorigenesis and would make a good therapeutic target. By utilizing three models (human tissue, animal models, and tissue culture) in which to characterize the role of SKP2 in breast cancer, we can obtain a better understanding of the molecular mechanisms underlying the aggressive tumor growth of basal-like breast tumors. It is anticipated that results from these studies will show that SKP2 would make a good therapeutic target for the treatment of women with basal-like tumors that are often associated with poor clinical outcome and tend to be ER-negative.
Body:
Task 1: During the second year of this three year study, I have obtained the necessary IRB approval to begin to collect archived formalin-fixed paraffin-embedded reductive mammoplaste and breast carcinoma tissues from the Department of Pathology, Baystate Medical Center. These tissues will be used to create tissue microarrays to be stained for SKP2, p27, phosphor-p27, CDK2, cyclin D1, and cyclin E. 
Key Research Accomplishments:
Training Accomplishments:  Obtained IRB approval from Baystate Medical Center to collect archived formalinfixed paraffin-embedded reductive mammoplaste and breast carcinoma tissues  Transfected TMX2-28 cells with SKP2-shRNA and successfully established a stably transfected cell line  Isolated protein from TMX2-28,SKP2 knockdown TMX2-28, MCF-7, and MDA-MB-231 cell lines
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SKP2 Targets p27 for Degradation
•Breast cancer is a heterogeneous disease that varies in its biology and response to therapy
•Basal-like tumors are associated with;
•A positive basal cytokeratin (CK) expression pattern (CK 5, 14 and/or 17)
•Negative expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)
•The objective of this research is to further our understanding of the cellular and molecular mechanisms underlying the aggressive growth of triplenegative/basal-like tumors
•S-phase kinase associated-protein 2 (SKP2) plays an important role in cell cycle regulation by targeting the cell cycle inhibitor p27 for degradation and subsequently promoting the progression into the S-phase of the cell cycle
•The novel cell line TMX2-28 was chosen as a model for ER-negative, basallike breast cancer because this particular cell line is highly aggressive, ERnegative, has a mixed basal/luminal cytokeratin (CK) expression pattern and overexpresses SKP2 • 300 additional ER-negative and triple-negative tumor cases to examine immunohistochemically 11  1  25  8  6  13  3  19  26  17  12  7  5  14  22  4  24  20  15  29  18  2  16  21  10  28  9  30  27 9 41
Funding S-Phase Kinase-Associated Protein 2 (SKP2) in Estrogen
•
SKP2 Expression in Human Tissue
•TMX2-28 is a triple-negative breast cancer cell line that constitutively expresses a basal-like cytokeratin pattern and overexpresses SKP2
•TMX2-28 cells al so overexpress a number of genes associated with SKP2 including p27, CDK2, and Cyclin E
•Knockdown of SKP2 expression by 63% does not significantly alter gene expression of its associated genes
•SKP2 was highly expressed in 46% (17 of 37) of ER-negative tumors, 24% (23 of 96) of ER-positive tumors, and 18% (9 of 50) reductive mammoplasty tissues
•SKP2 was also highly expressed in 77% (10 of 13) of triple-negative breast cancers while only 24% (24 of 99) of non-triple negative breast cancers had high expression of SKP2
